REMSleep Patent Application Has Been Allowed by the United States Patent and Trademark Office

Rhea-AI Summary

REMSleep Holdings, Inc. (OTCQB: RMSL) has received approval for another utility patent for its Nasal Ventilation System from the United States Patent and Trademark Office. The company expects to be awarded the patent in about 8 weeks after filing the necessary paperwork. REMSleep is awaiting silicone raw materials, expected to arrive in early October, to begin production of the Deltawave CPAP pillows interface.

Following the Deltawave launch, REMSleep plans to submit a 510K application for its next-generation product, 'Longevity', with an expected clearance time of approximately 5 months. The company also anticipates launching a third-generation CPAP interface mask by the end of 2025. REMSleep projects significant growth, expecting to become a substantial company by the end of 2025.

Positive

• Approval of another utility patent for Nasal Ventilation System
• Imminent production and launch of Deltawave CPAP pillows interface
• Planned 510K application for next-generation 'Longevity' product
• Development of third-generation CPAP interface mask by end of 2025
• Projected substantial company growth by end of 2025

Negative

• Potential delays in production due to supply chain issues for silicone raw materials
• 5-month waiting period for 510K clearance of 'Longevity' product

CLEARWATER, FL, Sept. 03, 2024 (GLOBE NEWSWIRE) -- REMSleep Holdings, Inc. (OTCQB: RMSL) announces that another utility patent for its Nasal Ventilation System has been allowed by the United States Patent and Trademark Office.  REMSleep will file the necessary paperwork to pay for issuance and, thereafter, REMSleep should be awarded a patent in approximately 8 weeks.  REMSleep will maintain a continuation application for adding any improvements and/or changes to the patent lineage.

REMSleep is now waiting on delivery of silicone raw materials from supply chain to produce inventory for market launch.  We are expecting materials to arrive to manufacturer approximately first week of October.  Production should be available a few days after and we will begin shipping samples to distributors, etc.  During this period, we are making all necessary preparations to be fully regulatory compliant with FDA for the launch of the Deltawave CPAP pillows interface.

Immediately after launch of the Deltawave REMSleep intends to submit 510K application for its next generation “Longevity”.  The Longevity CPAP pillows interface 510K application is expected to take approximately 5 months to clearance.  The “Longevity” design is complete, and no additional R&D is needed.  There will be a third generation CPAP interface mask to follow Longevity.  We expect to have the third-generation pillows mask to market by end of 2025.  We expect REMSleep to be a substantial company by end of 2025.

About REMSleep Holdings, Inc.

REMSleep Holdings, Inc. is a medical device manufacturer dedicated to forever changing the level of treatment provided to obstructive sleep apnea patients. Our focus is primarily designing and manufacturing devices and products for the treatment of sleep apnea and other respiratory conditions. With over 30 years of collective experience in CPAP therapy, the REMSleep team has extensive knowledge and understanding of CPAP and the challenges of patient compliance. We diligently strive for our products to make a difference and improve the condition of those suffering from sleep apnea.

Forward-looking Statements

This press release may contain forward-looking statements regarding the Company. All statements, other than statements of historical fact included herein, are "forward-looking statements" including statements regarding the Company’s future prospects and risks in investing in Company’s common stock. These statements are based upon the Company's current expectations and speak only as of the date hereof. Financial performance in one period does not necessarily mean continued or better performance in the future. The Company's actual results in any endeavor may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, which factors or uncertainties may be beyond our ability to foresee or control. Other risk factors include the status of the Company's common stock as a "penny stock" and those risk factors stated in reports filed with the U.S. Securities and Exchange Commission or SEC on its EDGAR website (URL:www.sec.gov)

Contact:
REMSleep Holdings, Inc.
14175 ICOT Blvd
Suite 300
Clearwater, FL 33760
Email: twood@remsleep.com
Phone: 912-590-2001

FAQ

When will REMSleep (RMSL) receive its new patent for the Nasal Ventilation System?

REMSleep expects to be awarded the patent in approximately 8 weeks after filing the necessary paperwork and paying for issuance.

What is the timeline for the production of REMSleep's (RMSL) Deltawave CPAP pillows interface?

REMSleep anticipates receiving silicone raw materials in early October, with production beginning a few days after and shipping of samples to distributors to follow.

What is REMSleep's (RMSL) plan for the 'Longevity' CPAP pillows interface?

REMSleep intends to submit a 510K application for the 'Longevity' product immediately after launching the Deltawave. The clearance process is expected to take approximately 5 months.

When does REMSleep (RMSL) expect to launch its third-generation CPAP interface mask?

REMSleep anticipates launching its third-generation CPAP interface mask by the end of 2025.